Contact Us
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
Heart failure affects millions of patients, yet early diagnosis remains a persistent challenge. In this session, hear from Neil Skolnik, MD; Ileana Piña, MD; and Nishant Shah, MD as they review the clinical evidence behind NT-proBNP and demonstrate how this guideline-recommended biomarker is being applied in real-world care to support more informed, timely decision-making.
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
Overview of the role of natriuretic peptides (NT-proBNP) testing in early heart failure detection and guideline recommendations to evaluate non-specific dyspnea.
Explains how team-based care allows clinicians to detect subclinical (Stage B) HF before symptomatic stages.
Links hypertension, diabetes, and obesity with heart failure. Real world evidence showing actionable improvement in HF outcomes.
Lays out a step-by-step algorithm to shift the diagnostic approach and offering therapeutic alternatives.
The shift from reactive care to early, proactive heart failure detection.